Inpharma 1516 - 3 Dec 2005

■ Ziprasidone provided "significant and sustainedheadache improvement" in three migraineurs withrefractory chronic daily headache, report researchersfrom Ireland. The women did not have asimultaneously active psychiatric disorder whenziprasidone 20–60 mg/day was started. The headacheswere associated with overuse of analgesics in at leasttwo of the women. Following ziprasidone initiation at20 mg/day, two of the women experienced asignificant and sustained reduction in headacheseverity scores from 1 and 2 weeks of treatment,respectively; for the third woman, the sameimprovement occurred within 4 days of ziprasidonebeing increased to 40 mg/day. The patients alsoexperienced reductions in headache frequency. Theonly adverse event reported was mild sedation in onewoman, which was not problematic.Cahill CM, et al. Treatment of refractory chronic daily headache with theatypical antipsychotic ziprasidone - a case series. Cephalalgia 25: 822-826, No.10, Oct 2005 801023882

1

Inpharma 3 Dec 2005 No. 15161173-8324/10/1516-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved